Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference


Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10th ? 13th in Miami Beach, Florida. The fireside chat will take place at 8:00 a.m. ET on June 12th.

A live webcast and replay of the fireside chat will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations/.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company's mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.


These press releases may also interest you

15 jun 2024
Biotech entrepreneur donates $50 million to UC Irvine School of Biological Sciences
The University of California, Irvine has received a $50 million donation from Orange County biotech entrepreneur Charlie Dunlop for the School of Biological Sciences. His gift will create an endowed fund that will provide unrestricted support for...

15 jun 2024
MEDIA ADVISORY - Minister Hajdu to make major announcement for Northern Ontario
Please be advised that the Honourable Patty Hajdu, Minister of Indigenous Services, will make a funding announcement for the Weeneebayko Area Health Authority. Date:  Monday, June 17, 2024Time: 12:00 p.m. (ET) Where:House of Commons Foyer (West...

15 jun 2024
Public advisory - Dianeal PD4 2.5% Dextrose and Physioneal 40 2.27% Glucose peritoneal dialysis solutions recalled due to risk of leakage at connection site
SummaryProducts: Dianeal PD4 2.5% Dextrose peritoneal dialysis solution (3,000 mL and 5,000 mL); Physioneal 40 2.27% Glucose peritoneal dialysis solution (2,500 mL)Issue: Health products ? Product safetyWhat to do: Immediately check your stock to see...

15 jun 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern...

15 jun 2024
IASO Bio Presented New Data of FUCASO® (Equecabtagene Autoleucel) for the Treatment of High-risk Newly Diagnosed Multiple Myeloma in Oral Presentation at EHA 2024
IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, presented clinical data on the use of Equecabtagene Autoleucel (Eque-cel),...

15 jun 2024
Genentech's Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) in combination with gemcitabine and...

More news about Health...


News published on and distributed by: